P. GamBe

This Raw Listing contains the General
Information Section and up to the first 5 pages.

```
 1                               SEQUENCE LISTING
 2
 3   (1)    General Information:
 4                                                ENTERED
 5       (i) APPLICANT: Brooks, Peter
 6                      Cheresh, David A
 7
 8      (ii) TITLE OF INVENTION: METHODS AND COMPOSITIONS USEFUL FOR
 9               INHIBITION OF ANGIOGENESIS
10
11     (iii) NUMBER OF SEQUENCES: 14
12
13      (iv) CORRESPONDENCE ADDRESS:
14           (A) ADDRESSEE: Office of Patent Counsel, The Scripps
15               Research Institute
16           (B) STREET: 10666 North Torrey Pines Road, TPC-8
17           (C) CITY: La Jolla
18           (D) STATE: CA
19           (E) COUNTRY: USA
20           (F) ZIP: 92037
21
22       (v) COMPUTER READABLE FORM:
23           (A) MEDIUM TYPE: Floppy disk
24           (B) COMPUTER: IBM PC compatible
25           (C) OPERATING SYSTEM: PC-DOS/MS-DOS
26           (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
27
28      (vi) CURRENT APPLICATION DATA:
29           (A) APPLICATION NUMBER: 09/081,522
30           (B) FILING DATE:
31           (C) CLASSIFICATION:
32
33     (vii) PRIOR APPLICATION DATA:
34           (A) APPLICATION NUMBER:US/08/210,715
35           (B) FILING DATE: 18-MAR-1994
36
37    (viii) ATTORNEY/AGENT INFORMATION:
38           (A) NAME: Fitting, Thomas
39           (B) REGISTRATION NUMBER: 34,163
40           (C) REFERENCE/DOCKET NUMBER: TSRI 419.0
41
42      (ix) TELECOMMUNICATION INFORMATION:
43           (A) TELEPHONE: (619) 554-2937
44           (B) TELEFAX: (619) 554-6312
45
46
```

```
47      (2) INFORMATION FOR SEQ ID NO:1:
48
49          (i) SEQUENCE CHARACTERISTICS:
50              (A) LENGTH: 6 amino acids
51              (B) TYPE: amino acid
52              (C) STRANDEDNESS: single
53              (D) TOPOLOGY: linear
54
55         (ii) MOLECULE TYPE: peptide
56
57        (iii) HYPOTHETICAL: NO
58
59         (iv) ANTI-SENSE: NO
60
61          (v) FRAGMENT TYPE: internal
62
63
64         (ix) FEATURE:
65              (A) NAME/KEY: Peptide
66              (B) LOCATION: 1..6
67              (D) OTHER INFORMATION: /label= BOC-GRGDFV-OMe
68                  /note= "BOC signifies the N-terminal protecting
69                  group butyloxycarbonyl; OMe signifies a C-terminal
70                  methyl ester;  arginine in the second position
71
72         (ix) FEATURE:
73              (A) NAME/KEY: Peptide
74              (B) LOCATION: 1..6
75              (D) OTHER INFORMATION: /label= OMe
76                  /note= "OMe signifies the C-terminal protecting
77                  group methyl ester."
78
79         (ix) FEATURE:
80              (A) NAME/KEY: Peptide
81              (B) LOCATION: 1..6
82              (D) OTHER INFORMATION: /label= D-Arg
83                  /note= "A prefix "D" in D-Arg signifies that the
84                  arginine in position 2 is a D-amino acid."
85
86
87         (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
88
89         Gly Arg Gly Asp Phe Val
90         1               5
91
92      (2) INFORMATION FOR SEQ ID NO:2:
93
94          (i) SEQUENCE CHARACTERISTICS:
95              (A) LENGTH: 6 amino acids
96              (B) TYPE: amino acid
97              (C) STRANDEDNESS: single
98              (D) TOPOLOGY: linear
99
```

PAGE: 3

RAW SEQUENCE LISTING
PATENT APPLICATION *US/09/081,522*

DATE: 03/21/2000
TIME: 11:56:04

INPUT SET: S35088.raw

```
100        (ii) MOLECULE TYPE: peptide
101
102       (iii) HYPOTHETICAL: NO
103
104        (iv) ANTI-SENSE: NO
105
106         (v) FRAGMENT TYPE: internal
107
108
109        (ix) FEATURE:
110             (A) NAME/KEY: Peptide
111             (B) LOCATION: 1..6
112             (D) OTHER INFORMATION: /label= BOC
113                   /note= "BOC signifies the N-terminal blocking
114                   group tertbutyloxycarbonyl."
115
116        (ix) FEATURE:
117             (A) NAME/KEY: Peptide
118             (B) LOCATION: 1..6
119             (D) OTHER INFORMATION: /label= OH
120                   /note= "OH signifies a free C-terminal carboxylic
121                   acid."
122
123        (ix) FEATURE:
124             (A) NAME/KEY: Peptide
125             (B) LOCATION: 1..6
126             (D) OTHER INFORMATION: /label= D-Arg
127                   /note= "A prefix "D" in D-Arg signifies that the
128                   arginine in position 2 is a D-amino acid."
129
130
131        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
132
133        Gly Arg Gly Asp Phe Val
134        1                   5
135
136  (2) INFORMATION FOR SEQ ID NO:3:
137
138         (i) SEQUENCE CHARACTERISTICS:
139             (A) LENGTH: 6 amino acids
140             (B) TYPE: amino acid
141             (C) STRANDEDNESS: single
142             (D) TOPOLOGY: linear
143
144        (ii) MOLECULE TYPE: peptide
145
146       (iii) HYPOTHETICAL: NO
147
148        (iv) ANTI-SENSE: NO
149
150         (v) FRAGMENT TYPE: internal
151
152
```

```
153        (ix) FEATURE:
154              (A) NAME/KEY: Peptide
155              (B) LOCATION: 1..6
156              (D) OTHER INFORMATION: /label= H
157                      /note= "H signifies a free N-terminal amine."
158
159        (ix) FEATURE:
160              (A) NAME/KEY: Peptide
161              (B) LOCATION: 1..6
162              (D) OTHER INFORMATION: /label= OH
163                      /note= "OH signifies a free C-terminal carboxylic
164                      acid."
165
166        (ix) FEATURE:
167              (A) NAME/KEY: Peptide
168              (B) LOCATION: 1..6
169              (D) OTHER INFORMATION: /label= D-Arg
170                      /note= "A prefix "D" in D-Arg at position 2,
171                      signifies that the arginine is a D-amino acid."
172
173
174        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
175
176        Gly Arg Gly Asp Phe Val
177        1                   5
178
179    (2) INFORMATION FOR SEQ ID NO:4:
180
181        (i) SEQUENCE CHARACTERISTICS:
182              (A) LENGTH: 6 amino acids
183              (B) TYPE: amino acid
184              (C) STRANDEDNESS: single
185              (D) TOPOLOGY: circular
186
187       (ii) MOLECULE TYPE: peptide
188
189      (iii) HYPOTHETICAL: NO
190
191       (iv) ANTI-SENSE: NO
192
193        (v) FRAGMENT TYPE: internal
194
195
196        (ix) FEATURE:
197              (A) NAME/KEY: Peptide
198              (B) LOCATION: 1..6
199              (D) OTHER INFORMATION: /label= cyclo
200                      /note= "Cyclo signifies a cyclic peptide; lower
201                      case letters indicate a D-amino acid; capital
202                      letters indicate a L-amino acid."
203
204
205        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
```

```
206
207          Gly Arg Gly Asp Phe Val
208          1                   5
209
210    (2) INFORMATION FOR SEQ ID NO:5:
211
212          (i) SEQUENCE CHARACTERISTICS:
213               (A) LENGTH: 5 amino acids
214               (B) TYPE: amino acid
215               (C) STRANDEDNESS: single
216               (D) TOPOLOGY: circular
217
218        (ii) MOLECULE TYPE: peptide
219
220      (iii) HYPOTHETICAL: NO
221
222       (iv) ANTI-SENSE: NO
223
224        (v) FRAGMENT TYPE: internal
225
226
227  .     (ix) FEATURE:
228               (A) NAME/KEY: Peptide
229               (B) LOCATION: 1..5
230               (D) OTHER INFORMATION: /label= cyclo
231                       /note= "Cyclo signifies a cyclic peptide; lower
232                       case letters indicate a D-amino acid; capital
233                       letters indicate a L-amino acid."
234
235
236        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
237
238          Arg Gly Asp Phe Val
239          1                 5
240
241    (2) INFORMATION FOR SEQ ID NO:6:
242
243          (i) SEQUENCE CHARACTERISTICS:
244               (A) LENGTH: 5 amino acids
245               (B) TYPE: amino acid
246               (C) STRANDEDNESS: single
247               (D) TOPOLOGY: circular
248
249        (ii) MOLECULE TYPE: peptide
250
251      (iii) HYPOTHETICAL: NO
252
253       (iv) ANTI-SENSE: NO
254
255        (v) FRAGMENT TYPE: internal
256
257
258        (ix) FEATURE:
```

SEQUENCE VERIFICATION REPORT
PATENT APPLICATION   *US/09/081,522*

DATE: 03/21/2000
TIME: 11:56:05

INPUT SET: S35088.raw

Line   Error   Original Text